Literature DB >> 20123477

Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses.

M J de Groot1, M Hoeksma, N Blau, D J Reijngoud, F J van Spronsen.   

Abstract

In untreated phenylketonuria (PKU), deficiency of phenylalanine hydroxylase (PAH) results in elevated blood phenylalanine (Phe) concentrations and severe mental retardation. Current dietary treatment prevents mental retardation, but cognitive outcome remains suboptimal. The mechanisms by which elevated blood Phe concentrations disturb cerebral metabolism and cognitive function have not been fully elucidated. In this review, we discuss different hypotheses on the pathogenesis of PKU, focusing on the effects of disturbed large neutral amino acid (LNAA) transport from blood to brain on cerebral neurotransmitter and protein synthesis. Although the definitive roles of these processes in PKU pathogenesis are not fully understood yet, both substantially influence clinical outcome. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20123477     DOI: 10.1016/j.ymgme.2009.10.016

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  72 in total

1.  Metabolomic changes demonstrate reduced bioavailability of tyrosine and altered metabolism of tryptophan via the kynurenine pathway with ingestion of medical foods in phenylketonuria.

Authors:  Denise M Ney; Sangita G Murali; Bridget M Stroup; Nivedita Nair; Emily A Sawin; Fran Rohr; Harvey L Levy
Journal:  Mol Genet Metab       Date:  2017-04-06       Impact factor: 4.797

Review 2.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

3.  Sight-threatening phenylketonuric encephalopathy in a young adult, reversed by diet.

Authors:  S Rubin; A L Le Piffer; M B Rougier; M N Delyfer; J F Korobelnik; I Redonnet-Vernhet; C Marchal; C Goizet; S Mesli; C Gonzalez; H Gin; V Rigalleau
Journal:  JIMD Rep       Date:  2013-02-12

4.  Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria.

Authors:  Anna Hood; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desirée A White
Journal:  Mol Genet Metab       Date:  2014-01-31       Impact factor: 4.797

5.  Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.

Authors:  Emily A Sawin; Sangita G Murali; Denise M Ney
Journal:  Mol Genet Metab       Date:  2014-02-08       Impact factor: 4.797

6.  The Use of d2 and Benton Tests for Assessment of Attention Deficits and Visual Memory in Teenagers with Phenylketonuria.

Authors:  Bozena Didycz; Magdalena Nitecka; Miroslaw Bik-Multanowski
Journal:  JIMD Rep       Date:  2017-09-24

7.  High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2015-11-26       Impact factor: 4.797

8.  Brain White Matter Integrity Mediates the Relationship Between Phenylalanine Control and Executive Abilities in Children with Phenylketonuria.

Authors:  Anna Hood; Jerrel Rutlin; Joshua S Shimony; Dorothy K Grange; Desiree A White
Journal:  JIMD Rep       Date:  2016-07-22

Review 9.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

10.  Biochemical, Metabolic, and Behavioral Characteristics of Immature Chronic Hyperphenylalanemic Rats.

Authors:  Gerald A Dienel; Nancy F Cruz
Journal:  Neurochem Res       Date:  2015-07-30       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.